
Sign up to save your podcasts
Or


In which Aaron speaks with Alex Chavez, MD-PhD about antiviral drug development. They discuss chemical strategies for protease inhibitor development and the details and rationale of a novel assay that allows for early validation of candidate drugs. Additionally Alex discusses newer collaborations he is engaged in to build cellular resistance to damaging radiation.
By Columbia Biotech Society5
44 ratings
In which Aaron speaks with Alex Chavez, MD-PhD about antiviral drug development. They discuss chemical strategies for protease inhibitor development and the details and rationale of a novel assay that allows for early validation of candidate drugs. Additionally Alex discusses newer collaborations he is engaged in to build cellular resistance to damaging radiation.

43,687 Listeners

756 Listeners

12,130 Listeners

818 Listeners

87,868 Listeners

113,121 Listeners

56,944 Listeners

9,556 Listeners

5,217 Listeners

4,807 Listeners

6,592 Listeners

85 Listeners

5,576 Listeners

29,272 Listeners

16,525 Listeners